SPIROXIS Trademark

Trademark Overview


On Wednesday, November 3, 2021, a trademark application was filed for SPIROXIS with the United States Patent and Trademark Office. The USPTO has given the SPIROXIS trademark a serial number of 79327764. The federal status of this trademark filing is REGISTERED as of Tuesday, April 11, 2023. This trademark is owned by Vicore Pharma AB. The SPIROXIS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals and medical preparations for human use, namely, prescription drugs, namely, pills, tablets, capsules, caplets, and liquid drops sachets for the treatment of pulmonary diseases, cardiovascular diseases, autoimmune and inflammatory diseases, fibrotic diseases and kidney diseases; pharmaceutical preparations for use within the fields of pulmonary diseases, cardiovascular diseases, autoimmune and inflammatory diseases, fibrotic diseases and kidney diseases; pharmaceutical preparations for treating and preventing pulmonary fibrosis, namely, idiopathic pulmonary fibrosis; pharmaceutical preparations for use in treating diffuse systemic sclerosis with lung manifestations; pharmaceutical preparations for treating infectious lung diseases; pharmaceutical preparations for treatment and prevention of covid-19
spiroxis

General Information


Serial Number79327764
Word MarkSPIROXIS
Filing DateWednesday, November 3, 2021
Status700 - REGISTERED
Status DateTuesday, April 11, 2023
Registration Number7021174
Registration DateTuesday, April 11, 2023
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 24, 2023

Trademark Statements


Goods and ServicesPharmaceuticals and medical preparations for human use, namely, prescription drugs, namely, pills, tablets, capsules, caplets, and liquid drops sachets for the treatment of pulmonary diseases, cardiovascular diseases, autoimmune and inflammatory diseases, fibrotic diseases and kidney diseases; pharmaceutical preparations for use within the fields of pulmonary diseases, cardiovascular diseases, autoimmune and inflammatory diseases, fibrotic diseases and kidney diseases; pharmaceutical preparations for treating and preventing pulmonary fibrosis, namely, idiopathic pulmonary fibrosis; pharmaceutical preparations for use in treating diffuse systemic sclerosis with lung manifestations; pharmaceutical preparations for treating infectious lung diseases; pharmaceutical preparations for treatment and prevention of covid-19

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, December 10, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameVicore Pharma AB
Party Type30 - Original Registrant
Legal Entity Type64 - NOT AVAILABLE
AddressSE

Party NameVicore Pharma AB
Party Type20 - Owner at Publication
Legal Entity Type64 - NOT AVAILABLE
AddressSE

Party NameVicore Pharma AB
Party Type10 - Original Applicant
Legal Entity Type64 - NOT AVAILABLE
AddressSE

Trademark Events


Event DateEvent Description
Sunday, October 22, 2023NEW REPRESENTATIVE AT IB RECEIVED
Monday, August 14, 2023FINAL DECISION TRANSACTION PROCESSED BY IB
Wednesday, July 26, 2023FINAL DISPOSITION NOTICE SENT TO IB
Wednesday, July 26, 2023FINAL DISPOSITION PROCESSED
Tuesday, July 11, 2023FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, April 11, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, April 11, 2023REGISTERED-PRINCIPAL REGISTER
Tuesday, January 24, 2023NOTIFICATION PROCESSED BY IB
Tuesday, January 24, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 24, 2023PUBLISHED FOR OPPOSITION
Wednesday, January 4, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, January 4, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, January 4, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, December 21, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 20, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 20, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, December 20, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 26, 2022REFUSAL PROCESSED BY IB
Friday, July 1, 2022NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, July 1, 2022REFUSAL PROCESSED BY MPU
Wednesday, June 29, 2022NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, June 28, 2022NON-FINAL ACTION WRITTEN
Wednesday, June 22, 2022ASSIGNED TO EXAMINER
Friday, January 21, 2022NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, December 14, 2021APPLICATION FILING RECEIPT MAILED
Friday, December 10, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 9, 2021SN ASSIGNED FOR SECT 66A APPL FROM IB